Login to Your Account



Pharma: Clinic Roundup


Thursday, May 17, 2012
• Pfizer Inc., of New York, said the Phase III INTORSECT study testing Torisel (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after Sutent (sunitinib malate) therapy did not meet the primary endpoint of prolonging progression-free survival (PFS) when compared to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription